Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: Clinicopathological features and prognostic significance

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4269-4275

  Queiroga, Felisbina Luisa ^a   Perez Alenza, Maria Dolores ^a   Silvan, Gema ^b   Peña, Laura ^b   Lopes, Carlos ^c   Illera, Juan Carlos ^b  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Animal model; Canine mammary tumors; Cox 2; Enzyme immunoassay; Inflammatory mammary carcinoma

Indexed keywords

CYCLOOXYGENASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DYSPLASIA; BREAST TUMOR; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DOG; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MASTITIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SKIN ULCER; TISSUE HOMOGENATE; TUMOR VOLUME;

ANIMALS; CYCLOOXYGENASE 2; DOGS; FEMALE; FOLLOW-UP STUDIES; MAMMARY NEOPLASMS, ANIMAL; NEOPLASM STAGING; PROGNOSIS;

EID: 27944438390     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Misdorp W: Veterinary cancer epidemiology. Vet Quart 18: 32-36, 1996.
2. Peréz-Alenza MD, Pena L, Del Castillo N and Nieto A: Factors influencing the incidence and prognosis of canine mammary tumors. J Small Anim Pract 41: 287-291, 2000.
3. Yamagami T, Kobayaashi T, Takahashi K and Sugiyama M: Prognosis for canine malignant mammary tumors based on TMN and histologic classification. J Vet Med Sci 58: 1079-1083, 1996.
4. Pena LL, Nieto AI, Perez-Alenza D, Cuesta P and Castano M: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 10: 237-246, 1998.
5. Nieto A, Pena L, Perez-Alenza MD, Sanchez MA, Flores JM and Castano M: Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 37: 239-247, 2000.
6. Sarli G, Preziosi R, Benazzi C, Castellani G and Marcato PS: Prognostic value of histologic stage and proliferative activity in canine malignant mammary tumors. J Vet Diagn Invest 14: 25-34, 2002.
7. Lee CH, Kim WH, Lim JH, Kang MS, Kim DY and Kweon OK: Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Science 5: 63-69, 2004.
8. Vail DM and MacEwen EG: Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-792, 2000.
9. Mohammed SI, Khan KN, Sellers RS, Hayek MG, DeNicola DB, Wu L, Bonney PL and Knapp DW: Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 70: 479-483, 2004.
10. Pena L, Perez-Alenza MD, Rodriguez-Bertos A and Nieto A: Canine inflammatory mammary carcinoma: histopathology, immunohistochemistry and clinical implications of 21 cases. Breast Cancer Res Treat 78: 141-148, 2003.
11. Chang S, Parker SL, Pham T, Buzdar AU and Hursting SD: Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute 1975-1992. Cancer 82: 2366-2372, 1998.
12. Kleer CG, van Golen KL and Merajver SD: Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2: 423-429, 2000.
13. Cristofanilli M, Budzar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, Booser D, Rivera E, Murray JL, Valero V, Ueno N, Singletary ES, Hunt K, Strom E, McNeese M, Stelling C and Hortobagyi GN: Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer 92: 1775-1782, 2001.
14. McCarthy NJ, Yang X, Linnoila IR, Merino MJ, Hewitt SM, Parr AL, Paik S, Steinberg SM, Hartmann DP, Mourali N, Levine PH and Swain SM: Microvessel density, expression of estrogen receptor α, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 8: 3857-3862, 2002.
15. Lerebours F, Bertheau P, Bieche I, Plassa LF, Champeme MH, Hacene K, Toulas C, Espie M, Marty M and Lidereau R: Two distinct groups of inflammatory breast cancer have distinct genotypes. Clin Cancer Res 9: 4184-4189, 2003.
16. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M and Lidereau R: Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10: 6789-6795, 2004.
17. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, Puig B, Geneix J, Hassoun J, Birnbaum D, Jacquemier J and Viens P: Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 202: 265-273, 2004.
18. Perez-Alenza MD, Tabanera E and Pena L: Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J Am Vet Med Assoc 19: 1110-1114, 2001.
19. Tavassoli FA: Infiltrating carcinoma: special types. Inflammatory carcinoma. In: Pathology of the Breast. 2nd edition. Tavassoli FA (ed.). McGraw-Hill, New York, pp. 538-541, 1999.
20. Schreinemachers DM and Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138-146, 1994.
21. Wang D and DuBois RN: Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 1: 64-73, 2004.
22. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2: 632-642, 2004.
23. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ and Trifan OC: Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 31: 551-557, 1999.
24. Crofford LJ: Cox-1 and Cox-2 tissue expression: implications and predictions. J Rheumatol Suppl 24: 15-19, 1997.
25. Howe LR, Subbaramaiah K, Brown AM and Dannenberg AJ: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8: 97-114, 2001.
26. Hwang D, Scollard D, Byrne J and Levine E: Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90: 455-460, 1998.
27. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J and Koki AT: Cox-2 is expressed in human pulmonary, colonie, and mammary tumors. Cancer 89: 2637-2645, 2000.
28. Half E, Tang XM, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681, 2002.
29. Yoshimura N, Sano H, Okamoto M, Akioka K, Ushigome H, Kadotani Y, Yoshimura R, Nobori S, Higuchi A, Ohmori Y and Nakamura K: Expression of cyclooxygenase-1 and -2 in human breast cancer. Surg Today 33: 805-811, 2003.
30. Ranger GS, Thomas V, Jewell A and Mokbel K: Elevated cyclooxygenase expression correlates with distant metastases in breast cancer. Anticancer Res 24: 2349-2351, 2004.
31. Gierse JK, Staten NR, Casperson GF, Koboldt CM, Trigg JS, Reitz BA, Pierce JL and Seibert K: Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2. Vet Ther 3: 270-280, 2002.
32. Khan KN, Knapp DW, Denicola DB and Harris K: Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 61: 478-481, 2000.
33. Pestili de Almeida EM, Piché C, Sorois J and Doré M: Expression of cyclo-oxygenase in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 49: 867-875, 2001.
34. McEntee MF, Cates JM and Neilsen N: Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet Pathol 39: 428-436, 2002.
35. Kleiter M, Malarkey DE, Ruslander DE and Thrall DE: Expression of cyclooxygenase-2 in canine epithelial nasal tumors. Vet Radiol Ultrasound 45: 255-260, 2004.
36. Doré M, Lanthier I and Sirois J: Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 40: 207-212, 2003.
37. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglung C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635, 2002.
38. Denkert C, Winze KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97: 2978-2987, 2003.
39. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R and Obrist P: Correlation of Cox-2 and Ep-CAM in human invasive breast cancer and its impact on survival. Br J Cancer 88: 574-578, 2003.
40. Kelly LM, Hill ADK, Kennedy S, Connolly EM, Ramanath R, The S, Dijkstra B, Purcell R, McDermott EW and O'Higgins N: Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol 29: 707-710, 2003.
41. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, Rody A, Greb RR, Bocker W and Kiesel L: Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382, 2003.
42. Owen LN: TMN Classification of Tumors in Domestic Animals. Ed. 1. World Health Organization, Geneva, 1980.
43. Misdorp W, Else RW, Helmen E and Lipscomb TP: Histological Classification of Mammary Tumors of the Dog and Cat. Published by Armed Forces Institute of Pathology and World Health Organization Second series, Washington 1999.
44. Bauer AK, Dwyer-Nield LD and Malkinson AM: High cyclooxygenase 1 (Cox-1) and cyclooxygenase 2 (Cox-2) contents in mouse lung tumors. Carcinogenesis 21: 543-550, 2000.
45. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A and Turpeenniemi-Hujanen T: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 89: 215-220, 2005.
46. Costa C, Scares R, Reis-filho JS, Leitão D, Amendoeira I and Schmitt FC: Cyclooxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55: 429-434, 2002.
47. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M and Franchi A: Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neeck squamous cell carcinoma. Hum Pathol 33: 708-714, 2002.
48. Davies G, Salter J, Hills M, Martin LA, Sacks N and Dowsett M: Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 9: 2651-2656, 2003.
49. Singh-Ranger G and Mokbel K: The role of cyclooxygenase (Cox-2) in breast cancer, and implications of Cox-2 inhibition. Eur J Surg Oncol 28: 729-737, 2002.
50. Sharpe CR, Collet JP, McNutt M, Belzile E and Hanley JA: Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83: 112-120, 2000.
51. Harris RE, Alshafie GA, Abou-Issa H and Seibert K: Chemoprevention of breast cancer in rats by celeCoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103, 2000.
52. Farivar-Mohseni H, Kandzari SJ, Zaslau S, Riggs DR, Jackson BJ and McFadden DW: Synergistic effects of Cox-1 and -2 inhibition on bladder and prostate cancer in vitro. Am J Surg 188: 505-510, 2004.
53. Knapp DW, Glickman NW, Mohammed SI, DeNicola DB, widmer WR, Bonney PL and DeGortari AE: Antitumor effects of piroxicam in spontaneous canine invasive urinary bladder cancer, a relevant model of human invasive bladder cancer. Adv Exp Med Biol 507: 377-380, 2002.
54. Pena L, Silvan G, Perez-Alenza MD, Nieto A and Illera JC: Steroid hormone profile of canine inflammatory mammary carcinoma: a preliminary study. J Steroid Biochem Mol Biol 43: 211-216, 2003.
55. Susanek SJ, Allen TA, Hoopes J, Withrow SJ and Macy DW: Inflammatory mammary carcinoma in the dog. J Am Vet Assoc 19: 971-976, 1983.
56. Anderson WF, Chu KC and Chang S: Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distint clinicopathologic entities?. J Clin Oncol 21: 2254-2259, 2003.
57. Resetkova E, Gonzalez-Angulo AM, Sneige N, Mcdonnell TJ, Buzdar AU, Kau SW, Yamamura Y, Reuben JM, Hortobagyi GN and Cristofanilli M: Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer 101: 913-917, 2004.